Drugs / AO-252
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06136884 | Nov 2023 → Jan 2027 expected | metastatic malignant neoplasm in the brain | A2A Pharmaceuticals Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-30 | A2A Pharmaceuticals Inc. | Results A2A TACC3 Program Clinical Progress in Womens Cancers a2apharma.com ↗
Significant (22% average over approximately 2 months) tumor reduction in 67% of the 4b (BID) cohort patients was observed. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-30 | A2A Pharmaceuticals Inc. | A2A TACC3 Program Clinical Progress in Womens Cancers a2apharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AO-252 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06136884 ↗ |
| Action | Inhibit | “a Protein-Protein Interaction Inhibitor of TACC3” NCT06136884 ↗ |
| Route | Oral | “administered oral tablets or capsules daily” NCT06136884 ↗ |
| Target | TACC3 | “a Protein-Protein Interaction Inhibitor of TACC3” NCT06136884 ↗ |